Compare KMPR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | AUPH |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | Canada |
| Employees | 7400 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2014 |
| Metric | KMPR | AUPH |
|---|---|---|
| Price | $32.91 | $15.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $47.67 | $17.25 |
| AVG Volume (30 Days) | 611.3K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $4.35 | $15.74 |
| P/E Ratio | $14.38 | ★ $7.78 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $28.41 | $7.29 |
| 52 Week High | $65.32 | $16.88 |
| Indicator | KMPR | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 57.29 |
| Support Level | $30.35 | $14.56 |
| Resistance Level | $41.66 | $16.32 |
| Average True Range (ATR) | 0.94 | 0.42 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 65.44 | 32.20 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.